RecruitingPHASE1, PHASE2NCT05278208
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Studying Anaplastic ependymoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Nationwide Children's Hospital
- Principal Investigator
- Margot Lazow, MDNationwide Children's Hospital
- Intervention
- LUTATHERA® (Lutetium Lu 177 dotatate)(drug)
- Enrollment
- 65 enrolled
- Eligibility
- 4-39 years · All sexes
- Timeline
- 2022 – 2027
Study locations (4)
- Children's Hospital Colorado, Aurora, Colorado, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05278208 on ClinicalTrials.govOther trials for Anaplastic ependymoma
Additional recruiting or active studies for the same condition.